Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
This program runs through December 31, 2027
In the absence of head-to-head comparisons, indirect evidence across heterogeneous trial populations with placebo or inferior active comparators provides limited guidance for clinical decision-making
Injection-site reactions such as redness, itching, or mild swelling may occur
Brown adipose tissue regulates glucose homeostasis and insulin sensitivity
Duffin et al
Current clinical consensus reflects the following: Research findings are preliminary and insufficient to guide treatment decisions No regulatory approval exists for using GLP-1s in addiction treatment Early signals do not outweigh the lack of long-term outcome data Instead, clinicians continue to recommend established, evidence-based approaches, including: Behavioral therapies tailored to substance use disorders Medication-assisted treatment when medically indicated Comprehensive psychosocial support and relapse-prevention planning Comprehensive assessment remains a cornerstone of safe and effective care
US$ 20.06
US$ 22.21
US$ 29.96
US$ 23.61
US$ 25.93
